Stem Cell Clinic

Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell…

By adminFebruary 4, 2021Stell Cell Research

February 02, 2021 14:21 ET | Source: Medexus Pharmaceuticals Inc

Orphan Designated Drug with August 2021 PDUFA date

Management to host conference call at 10:00 AM Eastern Time on February 3, 2021 and

Key Opinion Leader webinar to be held at 2:00 PM Eastern Time on February 5, 2021

TORONTO and CHICAGO and MONTREAL and WEDEL, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (Medexus) (TSXV: MDP) (OTCQX: MEDXF)(Frankfurt: P731) is pleased to announce that it and its wholly-owned United States-based subsidiary, Medexus Pharma, Inc. (Medexus Pharma and together with Medexus, the Company) entered into a Commercialization and Supply Agreement with medac Gesellschaft fr klinische Spezialprparate m.b.H. (medac), pursuant to which medac has granted Medexus Pharma an exclusive license to commercialize treosulfan, a bifunctional alkylating agent, in the United States (the License Agreement).

Treosulfan is an innovative, orphan-designated agent developed for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). If approved by the U.S. Food and Drug Administration (FDA), the Company expects that a treosulfan-based regimen will be the first in a new conditioning treatment class, Reduced Toxicity Conditioning, resulting in a unique combination of improved survival outcomes compared to reduced-intensity regimens and decreased toxicity compared to standard myeloablative regimens. A Prescription Drug User Free Act (PDUFA) date to review the New Drug Application (NDA) in respect of treosulfan by the FDA has been scheduled for August 2021.

The Company intends to leverage its strong, existing commercial infrastructure in the United States to address the underserved allo-HSCT market through its commercialization of treosulfan. medac conducted a phase III randomized study (the Phase III Study) comparing the results of treosulfan-based therapy with busulfan-based reduced intensity conditioning in advance of allo-HSCT for adult patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who were considered ineligible for standard myeloablative conditioning regimens. The planned confirmatory interim analysis of the Phase III Study demonstrated that non-inferiority was achieved in the treosulfan group compared to the busulfan group in two-year event-free survival with 64.0% (95% CI 56.070.9) in the treosulfan group and 50.4% (95% CI 42.857.5) in the busulfan group (HR 0.65 [95% CI 0.470.90]); p=0.0000164 (adjusted p-value for testing non-inferiority of treosulfan compared to busulfan).1Despite lacking indications for use in patients with AML or MDS, busulfan is the current market leading alkylating agent for allo-HSCT. Prior to genericization in 2016, busulfan reached peak annual sales of U.S. $126 million in the United States.2

The NDA in respect of treosulfan was filed by medac in August 2020 and seeks FDA approval for use of treosulfan as part of a conditioning regimen for allo-HSCT for adults with AML and MDS. The NDA is supported by the completed follow-up results from the Phase III Study covering all 570 randomized patients including superiority testing, which may result in even stronger claims than non-inferiority in a final label for treosulfan, if approved by the FDA.3

On April 8, 2015, the FDA granted medac Orphan Drug Designation for treosulfan as a conditioning treatment prior to allo-HSCT in malignant and non-malignant disease in adults and pediatric patients. In accordance with the Orphan Drug Act, seven years of exclusivity for this indication is expected upon FDA approval. According to the most recent data from the Center for International Blood & Marrow Transplant Research (CIBMTR), there were an estimated 9,028 allo-HSCT procedures in the United States in 2018, growing at about 3% year over year. Another 14,006 autologous-HSCT (auto-HSCT) procedures, which also routinely feature conditioning regimens that include alkylating agents, were completed that same year.4

Treosulfan was granted marketing authorization in combination with fludarabine by the European Commission in June 2019, indicated for use in combination with fludarabine as part of a conditioning treatment prior to allo-HSCT in (i) adult patients with both malignant and non-malignant diseases, and (ii) pediatric patients older than one month with malignant diseases. In Canada, Medexus is currently distributing treosulfan via the Special Access Program.

H. Joachim Deeg, MD, Professor of Medical Oncology at the University of Washington School of Medicine, Professor of Clinical Research at the Fred Hutchinson Cancer Research Center, and Physician at the Seattle Cancer Care Alliance, commented, Treosulfan has proven to be a potent drug for transplant conditioning in several phase II trials for both malignant and non-malignant disorders, conducted at our own Center and several other institutions, earning the label high intensity, low toxicity. Of note, clinically meaningful improvements in favor of the treosulfan group for event-free survival, overall survival, and transplant-related mortality were seen in medacs study, and a treosulfan-based regimen promises to be the preferred standard conditioning therapy for this study population, which represents the growing population of older and comorbid patients with AML or MDS, and beyond.

Mary Horowitz, MD,MS,Professor of Hematologic Research at the Medical College of Wisconsin andScientific Director for the CIBMTR, commented, It is incredibly important for clinicians to have more options for patients undergoing allo-HSCT. I am very happy to see that medac and Medexus have teamed up to work towards bringing treosulfan to the U.S. market. The data on treosulfan thus far is highly encouraging, suggesting it could fill an important gap for higher risk patients who cannot tolerate the typical toxicity profile of currently available high-intensity conditioning regimens.

The License Agreement

Upon entering into the License Agreement, Medexus Pharma paid medac a non-refundable upfront payment of U.S. $5 million. Under the terms of the License Agreement, Medexus Pharma must also pay medac (i) up to an aggregate of U.S. $55 million in non-refundable regulatory milestone payments, contingent upon the achievement of certain regulatory events in connection with the FDAs review process (the Regulatory Milestone Payments), and (ii) up to an aggregate of U.S. $40 million in non-refundable sales milestone payments, contingent upon Medexus Pharmas achievement of certain net sales goals (the Sales Milestone Payments, and together with the Regulatory Milestone Payments, the Milestone Payments). In addition, Medexus Pharma will pay medac a low single-digit royalty on its net sales of treosulfan in the United States.

The License Agreement is effective as of today and continues until the 10th anniversary of FDA approval of the initial NDA, unless earlier terminated by either the Company or medac in accordance with their respective rights under the License Agreement. Going forward, medac will continue with primary responsibility for development and regulatory matters in respect of treosulfan, including preparing and obtaining FDA approval of the initial NDA. After such FDA approval, Medexus Pharma will maintain regulatory approval of treosulfan in the United States and leverage its significant commercial experience in leading the commercialization effort for treosulfan. medac will also be responsible for the manufacturing and supply of treosulfan to Medexus Pharma in accordance with the terms of the License Agreement. The Company and medac will work together to finalize the preparations for commercialization of treosulfan ahead of the PDUFA date and expect to launch shortly after FDA approval.

Ken dEntremont, Chief Executive Officer of Medexus, stated, We are pleased to execute another transformative transaction with medac. In 2018, when we acquired medacs U.S. affiliate, we anticipated that treosulfan could be a significant advancement in HSCT. This transaction marks another major milestone for Medexus and is indicative of our continued effort to further expand into the U.S. through what we believe will be a highly accretive transaction for the Company. Given the drugs therapeutic profile and the data generated to date, we believe that treosulfan could exceed peak sales of busulfan of U.S. $126 million from use in allo-HSCT alone. This belief is re-enforced by the fact that that busulfan is currently being used off-label for the indications for which treosulfan has Orphan Drug Designation. Importantly, we believe there is a large unmet need as the current standard of care is not suitable for numerous at-risk groups, due to the high toxicity effects. Treosulfan has demonstrated excellent event-free survival and overall survival among such groups and as a result, should be well positioned to become the new standard of care in the U.S., with more than 100 publications supporting the safety and efficacy of treosulfan. We are proud to be working towards providing patients with a new solution that could have a very meaningful impact on their lives.

Jrg Hans, Chief Executive Officer of medac, emphasizes, This licensing deal with Medexus offers us the unique opportunity of providing patients and physicians with our very promising new treatment option in the area of allogeneic hematopoietic stem cell transplantation now also in the United States. The treosulfan-based conditioning regimen stands out for its combination of being highly effective - similar to the potency of the myeloablative procedure - while simultaneously exhibiting significantly reduced toxicity. We at medac are very proud of our first-in-class conditioning agent as it addresses a huge need in the area of conditioning treatments especially with regard to high-risk patients. Therefore, this product fully meets our company goals of improving patients quality of life and supporting healthcare professionals in the best possible way. As a shareholder in Medexus we see the expansion of our relationship as a true win-win.

Medexus and Medexus Pharma were represented by Munsch Hardt Kopf and Harr, P.C. and medac was represented by Baker & McKenzie LLP with respect to the License Agreement.

Conference Call Details

Medexus will host a conference call on February 3, 2021 at 10:00 AM Eastern Time (U.S. and Canada) to discuss the License Agreement and to provide an operational update.

The conference call will be available via telephone by dialing toll free 888-506-0062 for Canadian and U.S. callers or 973-528-0011 for international callers, or on the Medexus Investor Events section of the website: https://www.medexus.com/en_US/investors/news-events.

A webcast replay will be available on Medexus Investor Events section of the website (https://www.medexus.com/en_US/investors/news-events) through May 3, 2021. A telephone replay of the call will be available approximately one hour following the call, through February 10, 2021 and can be accessed by dialing 877-481-4010 for Canadian and U.S. callers or 919-882-2331 for international callers and entering conference ID: 39898

Key Opinion Leader Webinar

Medexus will be hosting a Key Opinion Leader webinar to discuss treosulfan on February 5, 2021 at 2:00 PM Eastern Time (U.S. and Canada), followed by a question-and-answer period. Ken dEntremont, CEO, will be joined by H. Joachim Deeg, MD to discuss the clinical data supporting treosulfan.

To join the webinar, please register here: Treosulfan Key Opinion Leader Webinar. After registering, you will receive a confirmation email containing information about joining the webinar. The webinar will also be live streamed on YouTube for those who are unable to use Zoom: YouTube Live Stream.

Questions may be asked during the webinar or can be emailed ahead of time to info@adcap.ca. A replay will be made available on the Medexus website.

H. Joachim Deeg, MD H. Joachim Deeg, MD, is a Physician at the Seattle Cancer Care Alliance, a Professor of Medical Oncology at the University of Washington School of Medicine, and a Professor of Clinical Research at the Fred Hutchinson Cancer Research Center. He currently holds the Miklos Kohary and Natalia Zimonyi Kohary Endowed Chair for Cancer Research. He is an expert in bone marrow transplantation, myelodysplastic syndromes, and myeloproliferative neoplasms. Dr. Deeg is a board-certified oncologist with more than 40 years of experience treating blood-disorders. He has a medical degree from the University of Bonn School of Medicine. Dr. Deeg completed his residency at the University of Rochester, NY and did a fellowship in Hematology/Oncology at the Fred Hutchinson Cancer Research Center/ University of Washington, Seattle.

Mary Horowitz, MDDr. Horowitz is the Robert A. Uihlein Professor of Hematologic Research and Deputy Cancer Center at the Medical College of Wisconsin in Milwaukee. She is also Scientific Director Emeritus of the Center for International Blood and Marrow Transplant Research (CIBMTR). The CIBMTR is a research collaboration between the National Marrow Donor Program(NMDP)/Be The Matchand the Medical College of Wisconsin. The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation and cellular therapy worldwide to increase survival and enrich quality of life for patients. The CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of transplant centers, and a unique and extensive clinical outcomes database. Dr. Horowitz also leads the Coordinating Center of the U.S. Blood and Marrow Clinical Trials Network, a multicenter group funded by the National Institutes of Health to test new therapies to improve the safety and effectiveness of transplantation. She has co- authored more than 400 publications addressing diverse issues in clinical BMT.

1Beelen, DW et al., Final Results of a Prospective Randomized Multicenter Phase III Trial Comparing Treosulfan / Fludarabine to Reduced Intensity Conditioning with Busulfan / Fludarabine Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Elderly or Comorbid Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Blood. 2017;130 (Suppl 1):521

2Symphony Health PHAST Data 2020

3Beelen, DW et al. Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens. Biol Blood Marrow Transplant 25 (2019) S1-S6, p. 53, Abstract No. 04.

4D'Souza, A, Fretham C, Lee SJ, et al. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2020 May 11: S1083-8791(20)30225-1

About medac GmbH

medac GmbH is a privately held, global pharmaceutical company with a growing pharmaceutical and diagnostics business. Since its foundation in Germany in 1970, medac has been specializing in the treatment of diseases within the indication areas oncology, hematology, urology and autoimmune disorders. medac is committed to the refinement of existing and the development of new therapeutic products always with the focus on improving patients quality of life. medac has become known for developing innovative products also in less common indications. This dedication has resulted in a comprehensive portfolio of pharmaceutical products that help make a difference in the lives of patients. medac continually invests in its product development and manufacturing as well as logistic capacities to meet both patients needs and the demands of healthcare professionals.

About Medexus Pharmaceuticals Inc.

Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Companys vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Companys leading products are: Rasuvo and Metoject, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall, an innovative prescription allergy medication with a unique mode of action.

For more information, please contact:

Ken dEntremont, Chief Executive Officer Medexus Pharmaceuticals Inc. Tel.: 905-676-0003 E-mail:ken.dentremont@medexus.com

Roland Boivin, Chief Financial Officer Medexus Pharmaceuticals Inc. Tel.: 514-334-8765 E-mail:roland.boivin@medexus.com

Investor Relations (U.S.): Crescendo Communications, LLC Tel: +1-212-671-1020 Email:mdp@crescendo-ir.com

Investor Relations (Canada): Tina Byers Investor Relations Tel: 905-330-3275 E-mail:tina@adcap.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

READER ADVISORIES

Forward Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements). The words anticipates, believes, expects, should, will, and similar expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Specific forward-looking statements contained in this press release include, but are not limited to, statements with respect to the August 2021 PDUFA date, expectations for treosulfan to be the first in a new conditioning treatment class, the Companys intention to leverage its commercial infrastructure in the United States to commercialize treosulfan, the expectation for exclusivity for treosulfan upon FDA approval, the results of the Phase III Study and the possibility of non-inferiority or stronger claims in the final label for treosulfan, the expected launch of treosulfan, the accretive nature of the transaction, the potential for treosulfan to exceed peak sales of busulfan and the anticipated growth in sales of, the market for and distribution of, treosulfan. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include those set out in the Companys materials filed with the Canadian securities regulatory authorities from time to time, including the Companys most recent annual information form and managements discussion and analysis; future capital requirements; intellectual property protection and infringement risks; competition (including potential for generic competition); reliance on key management personnel; the Companys ability to implement its business plan; the Companys ability to leverage its United States and Canadian infrastructure to promote additional growth, including with respect to the infrastructure of Medexus Pharma, and the potential benefits the Company expects to derive therefrom; regulatory approval by the FDA; litigation risk; and government regulation. Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of the date hereof. Other than as specifically required by law, the Company undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.

See the rest here:
Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell...

People With Cancer Should Receive COVID-19 Vaccine, Experts Say – Cancer Health Treatment News

By adminFebruary 4, 2021Stell Cell Research

People living with cancerincluding those undergoing treatmentshould receive COVID-19 vaccines as soon as they are available, according to new guidelines from the National Comprehensive Cancer Network (NCCN).

While people with some types of cancer and those receiving certain cancer treatments may not respond quite as well, the vaccines should still provide partial protection, which is especially important because some cancer patients are at higher risk for COVID-19 complications.

Right now, there is urgent need and limited data, said committee co-leader Steve Pergam, MD, MPH,of the Seattle Cancer Care Alliance and the Fred Hutchinson Cancer Research Center, headquarters of the National Institutes of Healths COVID-19 Prevention Network. Our number one goal is helping to get the vaccine to as many people as we can. That means following existing national and regional directions for prioritizing people who are more likely to face death or severe illness from COVID-19. The evidence we have shows that people receiving active cancer treatment are at greater risk for worse outcomes from COVID-19, particularly if they are older and have additional comorbidities, like immunosuppression.

Much remains to be learned about COVID-19 in people with cancer. Studies have shown that people with blood cancers like leukemia or lymphoma and lung cancer are at greater risk for severe COVID-19 and death, but those with other types, such as breast or lung cancer, do not appear to be at higher risk. Patients with active or advanced cancer are likely to fare worse. Although studies of the effects of cancer treatment on COVID-19 outcomes have yielded conflicting results, therapies that cause immune suppression seem to lead to poorer outcomes.

Two mRNA vaccines from Pfizer/BioNTech and Moderna were authorized by the Food and Drug Administration in December. These vaccines were 95% and 94% effective for preventing symptomatic COVID-19 in Phase III clinical trials. Vaccine candidates from AstraZeneca, Johnson and Johnson and Novavax are also effective, especially for preventing severe disease, and are likely to receive emergency use authorization in the coming months. All the vaccines were shown to be safe.

A Centers for Disease Control and Prevention (CDC) advisory committee developed a vaccine prioritization plan that puthealth care workers and residents of long-term care facilitiesfirst in line, followed bypeople overage 75 and certain frontline essential workers. The CDC later expanded eligibility to include everyone over 65 and people with underlying health conditionsincluding cancerthat put them at risk for more severe COVID-19. But current supplies are nowhere near adequate to vaccinate everyone whos eligible.

The NCCNs COVID-19 Vaccine Committee, which includes top hematology and oncology experts in the areas of infectious diseases, vaccine development and delivery, medical ethics and health information technology, recommends that all people with cancer should get a vaccine. The committee also advises that caregivers and people living in the same household with cancer patients should also get vaccinated when they are eligible.

While clinical trials have shown that the vaccines are highly effective at reducing the risk of becoming ill with COVID-19, it is still not clear how well they prevent asymptomatic infection and transmission, so the committee emphasizes the importance of continuing to follow precautions such as wearing masks and social distancing.

Although people on cancer treatment were excluded from the COVID-19 vaccine trials, experts say theres no reason to think the vaccines wont be safe for this group. The currently authorized vaccines do not contain live virus and therefore cannot cause disease, even in immunocompromised people.

The data we have on these vaccines shows theyre remarkably safe in the general population based on the trials. Admittedly, very few patients with active cancer or in active therapy were included in the trials. But having gone through all the documentation for both of these vaccines, it looks remarkably safe, Gary Lyman, MD, of Fred Hutch, who helped start the COVID-19 and Cancer Consortium, told the Fred Hutch News Service. I have no real concerns that there will be big surprises when it comes to safety for the cancer patient population. The risk to these patients from COVID is high and the risks from the vaccines appear very low.

While the vaccines appear safe for people with cancer, some patients may not respond as well, particularly those whose cancer or treatment causes immune suppression. Some blood cancers affect B cells, the white blood cells that produce antibodiesa key player in vaccine response. Chemotherapy and radiation can deplete white blood cells, and people undergoing stem cell transplants or receiving CAR-T therapy have their own immune cells killed off with chemo or radiation to make room for the new cells.

The NCCN committee recommends that people receiving intensive chemotherapy for leukemia should wait to be vaccinated until their white blood cell count recovers. Stem cell transplant and CAR-T recipients should delay vaccination until three months after the procedure to improved the chances that the vaccine will produce a good immune response. People undergoing major surgery should wait at least a few days. But everyone elseincluding patients receiving chemotherapy for solid tumors, targeted therapy, immunotherapy or radiation therapyshould get a vaccine as soon as they can.

If it is necessary to prioritize among people with cancer, the committee recommends moving those on active treatment (except those taking only hormone therapy), those who plan to start treatment soon and those who have recently finished treatment to the front of the line. Cancer patients with other risk factors, including older age and additional health conditions, should also be prioritized.

Finally, the guidance acknowledges the disparities and social inequities related to COVID-19Black and Latino people are more likely to be exposed to the coronavirus and more likely to develop severe disease and die from it, but are less likely to get vaccinated.

One of our primary goals is reducing morbidity and mortality, saidSirisha Narayana, MD,chair of the University of California at San Francisco Ethics Committee. We also have to take social determinants of health into account and make special efforts for people in high-risk communities.

The medical community is rising to one of the biggest challenges we have ever faced, addedNCCN CEO Robert Carlson, MD. The COVID-19 vaccines exemplify the heights of scientific achievement. Now we have to distribute them quickly, equitably, safely and efficiently, using clearly defined and transparent principles.

Given their higher risk for COVID-19, the NCCN, the American Society of Clinical Oncology and other advocates are asking that people with cancer be given priority for vaccination.

People with metastatic and active cancers die at a rate similar to people over age 75; if we die at the rate of 75 year olds we should be vaccinated with the 75 year olds, Kelly Shanahan, an advocate living with metastatic breast cancer, told Cancer Health. Those of us with active and metastatic cancers dont have the luxury of just staying home. We must get our treatments and scans and see our oncologists. Keep us out of the hospitalsand morguesby prioritizing us for the COVID19 vaccinations!

Click here to read the full NCCN COVID-19 vaccine guidance.

Click here for more news about COVID-19. For more, visit our sister site, COVID Health.com.

Adipose Tissue-Derived Stem Cells (ADSCS) Market is Projected to Grow Massively in Near Future The Courier – The Courier

By adminFebruary 4, 2021Stell Cell Research

Adipose Tissue-Derived Stem Cells (ADSCS) Market Research Reportconducts a deep estimation of the present state of the Adipose Tissue-Derived Stem Cells (ADSCS) Industry with the definition, classification, and market scope. The data included in the report has been generated by consulting industry leaders and taking inputs from them. The topmost subdivisions of the market have been emphasized and these divisions have been presented by giving statistics on their current state by the end of the forecast horizon.

Adipose Tissue-Derived Stem Cells (ADSCS) Market Insight:

Adipose tissue-derived stem cells (ADSCS) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account grow at a CAGR of 6.1% in the above-mentioned forecast period. The accelerating application of adipose tissue-derived stem cells (ADSCS) in the regenerative medicines research, development of cell linage, tissue engendering, bone and cartilage regeneration are driving the exponential growth of adipose tissue-derived stem cells (ADSCS) market during the forecast period of 2020 to 2027.

Get Free Full PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) at:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

Prominent Key Players Covered in the report:

Antria Inc., CELGENE CORPORATION, pluristem, Tissue Genesis, Cytori Therapeutics Inc., PRECIGEN, Mesoblast Ltd, CORESTEM, Inc, among other domestic and global players.

Adipose Tissue-Derived Stem Cells (ADSCS) Market Segmentation:

This report onthe Adipose Tissue-Derived Stem Cells (ADSCS) market is a detailed research study that helps provides answers and pertinent questions with respect to the emerging trends and growth opportunities in this industry. It helps identify each of the prominent barriers to growth, apart from identifying the trends within various application segments of the Global market for Feed Cellulase. Gathering historical and recent data from various authentic resources and depending on all the factors and trends, the report presents a figurative estimate of the future market condition, along with compound annual growth rate (CAGR).

Geographical Base of Global Adipose Tissue-Derived Stem Cells (ADSCS) Market:

Get Table Of Contents of This Premium Research For Free @https://www.databridgemarketresearch.com/toc/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

Research objectives:

In the end, the report makes some important proposals for a new project of Global Adipose Tissue-Derived Stem Cells (ADSCS) Market Industry before evaluating its feasibility. Overall, the report provides an in-depth insight into the Global Adipose Tissue-Derived Stem Cells (ADSCS) Market industry covering all important parameters. The report uses SWOT analysis for the growth assessment of the outstanding Global Adipose Tissue-Derived Stem Cells (ADSCS) Market players. It also analyzes the most recent enhancements while estimating the expansion of the foremost Global Adipose Tissue-Derived Stem Cells (ADSCS) Market players. It offers valuable information such as product offerings, revenue segmentation, and a business report of the commanding players in the global Global Adipose Tissue-Derived Stem Cells (ADSCS) Market.

In conclusion,Adipose Tissue-Derived Stem Cells (ADSCS) Marketreport presents the descriptive analysis of the parent market based on elite players, present, past and futuristic data which will serve as a profitable guide for all the Adipose Tissue-Derived Stem Cells (ADSCS) Market competitors.

Make an Inquiry of theAdipose Tissue-Derived Stem Cells (ADSCS) Market Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

We are grateful to you for reading our report. If you wish to find more details of the report or want customization, contact us. You can get a detail of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

Go here to see the original:
Adipose Tissue-Derived Stem Cells (ADSCS) Market is Projected to Grow Massively in Near Future The Courier - The Courier

Stem Cells- Definition, Properties, Types, Uses, Challenges

By adminFebruary 4, 2021Somatic Stem Cells

Biology Educational Videos

Last Updated on October 12, 2020 by Sagar Aryal

Stem cells are unique cells present in the body that have the potential to differentiate into various cell types or divide indefinitely to produce other stem cells.

Figure: Stem Cell Renewal and Differentiation. Image Source: Maharaj Institute of Immune Regenerative Medicine.

All the stem cells found throughout all living systems have three important properties. These properties can be visualized in vitro by a process called clonogenic assays, where a single cell is assessed for its ability to differentiate.

The following are some properties of stem cells:

Figure: Techniques for generating embryonic stem cell cultures. Image Source: John Wiley & Sons, Inc. (Nico Heins et al.)

Depending on the source of the stem cells or where they are present, stem cells are divided into various types;

Figure: Human Embryonic Stem Cells Differentiation. Image created with biorender.com

Figure: Preliminary Evidence of Plasticity Among Nonhuman Adult Stem Cells. Image Source: NIH Stem Cell Information.

Figure: Progress in therapies based on iPSCs. Image Source: Nature Reviews Genetics (R. Grant Rowe & George Q. Daley).

Figure: Mesenchymal stem cells (MSCs). Image Source: PromoCell GmbH.

Some of the common and well-known examples of stem cell research are:

Stem cell research has been used in various areas because of their properties. Some of the common applications of stem cells research include;

Because of different ethical and other issues related to stem cell research, there are some limitations or challenges of stem cell research. Some of these are:

Stem Cell Study Illuminates the Cause of a Devastating Inherited Heart Disorder – Newswise

By adminFebruary 4, 2021Stem Cell Medicine

Newswise PHILADELPHIAScientists in the Perelman School of Medicine at the University of Pennsylvania have uncovered the molecular causes of a congenital form of dilated cardiomyopathy (DCM), an often-fatal heart disorder.

This inherited form of DCM which affects at least several thousand people in the United States at any one time and often causes sudden death or progressive heart failure is one of multiple congenital disorders known to be caused by inherited mutations in a gene called LMNA. The LMNA gene is active in most cell types, and researchers have not understood why LMNA mutations affect particular organs such as the heart while sparing most other organs and tissues.

In the study, published this week in Cell Stem Cell, the Penn Medicine scientists used stem cell techniques to grow human heart muscle cells containing DCM-causing mutations in LMNA. They found that these mutations severely disrupt the structural organization of DNA in the nucleus of heart muscle cells but not two other cell types studied leading to the abnormal activation of non-heart muscle genes.

Were now beginning to understand why patients with LMNA mutations have tissue-restricted disorders such as DCM even though the gene is expressed in most cell types, said study co-senior author Rajan Jain, MD, an assistant professor of Cardiovascular Medicine and Cell and Developmental Biology at the Perelman School of Medicine.

Further work along these lines should enable us to predict how LMNA mutations will manifest in individual patients, and ultimately we may be able to intervene with drugs to correct the genome disorganization that these mutations cause, said study co-senior author Kiran Musunuru, MD, PhD, a professor of Cardiovascular Medicine and Genetics, and Director of the Genetic and Epigenetic Origins of Disease Program at Penn Medicine.

Inherited LMNA mutations have long puzzled researchers. The LMNA gene encodes proteins that form a lacy structure on the inner wall of the cell nucleus, where chromosomes full of coiled DNA are housed. This lacy structure, known as the nuclear lamina, touches some parts of the genome, and these lamina-genome interactions help regulate gene activity, for example in the process of cell division. The puzzle is that the nuclear lamina is found in most cell types, yet the disruption of this important and near-ubiquitous cellular component by LMNA mutations causes only a handful of relatively specific clinical disorders, including a form of DCM, two forms of muscular dystrophy, and a form of progeria a syndrome that resembles rapid aging.

To better understand how LMNA mutations can cause DCM, Jain, Musunuru, and their colleagues took cells from a healthy human donor, and used the CRISPR gene-editing technique to create known DCM-causing LMNA mutations in each cell. They then used stem cell methods to turn these cells into heart muscle cells cardiomyocytes and, for comparison, liver and fat cells. Their goal was to discover what was happening in the mutation-containing cardiomyocytes that wasnt happening in the other cell types.

The researchers found that in the LMNA-mutant cardiomyocytes but hardly at all in the other two cell types the nuclear lamina had an altered appearance and did not connect to the genome in the usual way. This disruption of lamina-genome interactions led to a failure of normal gene regulation: many genes that should be switched off in heart muscle cells were active. The researchers examined cells taken from DCM patients with LMNA mutations and found similar abnormalities in gene activity.

A distinctive pattern of gene activity essentially defines what biologists call the identity of a cell. Thus the DCM-causing LMNA mutations had begun to alter the identity of cardiomyocytes, giving them features of other cell types.

The LMNA-mutant cardiomyocytes also had another defect seen in patients with LMNA-linked DCM: the heart muscle cells had lost much of the mechanical elasticity that normally allows them to contract and stretch as needed. The same deficiency was not seen in the LMNA-mutant liver and fat cells.

Research is ongoing to understand whether changes in elasticity in the heart cells with LMNA mutations occurs prior to changes in genome organization, or whether the genome interactions at the lamina help ensure proper elasticity. Their experiments did suggest an explanation for the differences between the lamina-genome connections being badly disrupted in LMNA-mutant cardiomyocytes but not so much in LMNA-mutant liver and fat cells: Every cell type uses a distinct pattern of chemical marks on its genome, called epigenetic marks, to program its patterns of gene activity, and this pattern in cardiomyocytes apparently results in lamina-genome interactions that are especially vulnerable to disruption in the presence of certain LMNA mutations.

The findings reveal the likely importance of the nuclear lamina in regulating cell identity and the physical organization of the genome, Jain said. This also opens up new avenues of research that could one day lead to the successful treatment or prevention of LMNA-mutations and related disorders.

Other co-authors of the study were co-first authors Parisha Shah and Wenjian Lv; and Joshua Rhoades, Andrey Poleshko, Deepti Abbey, Matthew Caporizzo, Ricardo Linares-Saldana, Julie Heffler, Nazish Sayed, Dilip Thomas, Qiaohong Wang, Liam Stanton, Kenneth Bedi, Michael Morley, Thomas Cappola, Anjali Owens, Kenneth Margulies, David Frank, Joseph Wu, Daniel Rader, Wenli Yang, and Benjamin Prosser.

Funding was provided by the Burroughs Wellcome Career Award for Medical Scientists, Gilead Research Scholars Award, Pennsylvania Department of Health, American Heart Association/Allen Initiative, the National Institutes of Health (DP2 HL147123, R35 HL145203, R01 HL149891, F31 HL147416, NSF15-48571, R01 GM137425), the Penn Institute of Regenerative Medicine, and the Winkelman Family Fund for Cardiac Innovation.

###

Penn Medicineis one of the worlds leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of theRaymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nations first medical school) and theUniversity of Pennsylvania Health System, which together form a $8.6 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according toU.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.

The University of Pennsylvania Health Systems patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Centerwhich are recognized as one of the nations top Honor Roll hospitals byU.S. News & World ReportChester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nations first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.

View original post here:
Stem Cell Study Illuminates the Cause of a Devastating Inherited Heart Disorder - Newswise

iSpecimen expands offerings to support regenerative medicine, adding cryopreserved stem and immune cells to existing biospecimens available through…

By adminFebruary 4, 2021Stem Cell Medicine

LEXINGTON, Mass., Feb. 3, 2021 /PRNewswire/ -- iSpecimen today announced it has expanded its cellular biospecimen offeringsby introducing new cryopreserved stem and immune cell products for life science research and preclinical drug development. The new products are intended to support the growth of regenerative medicine by giving researchers broader access to the materials they need to develop new therapies.

Peripheral blood mononuclear cells (PBMCs), also provided as "leukopacks," are critical for the research and development of stem cell and immunotherapies, vaccines, diagnostics, and new treatments for cancer, infectious, and autoimmune diseases. PBMCs are an important source of CD34+Hematopoietic Stem Cells (HSCs), CD3+ Pan T cells, CD4+Helper T cells, CD8+Cytotoxic T cells, CD56+ Natural Killer (NK) cells, CD14+Monocytes, antibody-secreting CD19+ B cells, and other primary cell types that are commonly used in cell-based assays to help advance drug discovery and development.

iSpecimen provides centralized access to a repository of banked cell types available for prompt delivery, plus mononuclear cells that can be collected prospectively and subsequently cryopreserved, depending on project and specific donor phenotype requirements. When compared to fresh cell collections, cryopreserved products provide researchers with increased flexibility in the timing and rollout of their research studies, especially when dealing with unexpected changes to lab schedules or pandemic-related disruptions. Moreover, cryopreserved cells collected from multiple donor phenotypes may helpresearchers execute side-by-side studies within preclinical development workflows.

The new offerings, which supplement iSpecimen's line of fresh immune cells, include:

"We're committed to supplying life science researchers with more of what they need in some of medical research's most promising areas," said Wayne Vaz, iSpecimen's vice president of growth and corporate development. "To provide a broad choice for demanding research, we continue to focus on expanding our extensive network of trusted suppliers, increasing industry access to difficult-to-source specimens, and providing a proprietary Marketplace platform that improves the overall experience of acquiring annotated biomaterials."

Trusted, accredited partners

iSpecimen sources these stem and immune cells from a wide network of supplier donor facilities. Each leukopack has been collected and/or cryopreserved in a US-FDA registered, AABB-accredited cell collection and storage center using a controlled-rate freezer and validated processing protocols.

Streamlined discovery, access, and procurement

Researchers can access the new selection of cells, as well as a range of other human biospecimens, by contacting iSpecimen directly and through the iSpecimen Marketplace, an online platform that increases access to human biospecimens from specific patients and healthy donors who provide them.

For those needing cells, the iSpecimen Marketplace gives researchers centralized, single-source access to a growing population of healthy donors and patients with hematopoietic and immune cell phenotypes that can match particular research study criteria.

Hematopoietic stem and immune cells may be selected based upon a variety of donor phenotype parameters such as HLA type, blood type, body mass index, ethnicity, race, age, and gender. The iSpecimen Marketplace also offers a comprehensive donor screening capability, permitting researchers to select the required scope of infectious disease testing such as CMV, hepatitis (B&C), HIV, West Nile Virus, syphilis, Chagas, and more.

About iSpecimen

Headquartered in Lexington, MA, iSpecimen offers an online marketplace for human biospecimens, providing researchers with the specimens they need from the patients they want. The privately held company has developed theiSpecimen Marketplace, an online platform connecting healthcare organizations that have access to patients and specimens with the scientists who need them. Proprietary, cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. Researchers easily and compliantly gain access to specimens to drive scientific discovery. Partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. Ultimately, healthcare advances for all. For more information about iSpecimen, please visitwww.ispecimen.com.

SOURCE iSpecimen

Home

Excerpt from:
iSpecimen expands offerings to support regenerative medicine, adding cryopreserved stem and immune cells to existing biospecimens available through...

CU Researchers Win Prize from National Eye Institute – CU Anschutz Today

By adminFebruary 4, 2021Stem Cell Medicine

Natalia Vergara, PhD, assistant professor of ophthalmology at the University of Colorado School of Medicine, has been awarded a 3D ROC prize by the National Eye Institute (NEI) for her research teams work to create better models to accelerate the development of new therapies for retinal diseases.

The prize competition was established by the NEI to promote research on creating improved three-dimensional retinas in vitro, known as retinal organoids, derived from human stem cells,that can help researchers across the country with their work. The full name of the 3D ROC competition is 3D Retina Organoid Challenge.

Vergara and her team were the awardees in Phase II of the NEIs 3D ROC competition, receiving $60,000 for their work developing an organoid model that mimics the composition of the human retina and can respond to light. A key innovation of the teams project was the use of engineered stem cells that allow different cell types in these retinas to fluoresce in different colors, and the combination of this system with a state-of-the-art technology that enables the quantification of those cells in real time. This breakthrough allows for the application of human retinal organoids to the screening and validation of drugs as potential treatments for blinding diseases.

Vergara conducts research on the Anschutz Medical Campus and she is a member of CellSight, a multidisciplinary research initiative that aims to develop stem cell-based therapeutics to save and restore sight in patients with blinding diseases.

In the past decade, the advent of human stem cell-derived retinal organoid models created new opportunities to improve the drug development pipeline by increasing efficiency and decreasing costs. These models make it possible to test drug candidates in three-dimensional human retinal tissues.

The challenge for researchers has been standardizing the process of developing the retinal organoids from induced pluripotent stem cells. Through its work, Vergaras team has been able to create a process for making light responsive retinal organoids that have consistent structure and cellular composition. The researchers process also improved the yield of retinal organoids and allows researchers to track the cells over a period of time.

Vergara and her fellow CellSight researcher, Valeria Canto-Soler, PhD, describe the research in the video Improved Fluorescent Reporter Quantification-Based 3D Retinal Organoid Paradigm for Drug Screening. The project is a collaboration with researchers at Miami University, and Nanoscope Technologies.

Continued here:
CU Researchers Win Prize from National Eye Institute - CU Anschutz Today

Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy f – PharmiWeb.com

By adminFebruary 4, 2021Induced Pluripotent Stem Cells

DGAP-News: Evotec SE / Key word(s): Miscellaneous 04.02.2021 / 07:30 The issuer is solely responsible for the content of this announcement.

Hamburg, Germany, 04 February, 2021: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf ("UKE") for the development of a highly innovative first-in-class cell therapy approach for the treatment of heart failure.

Under the terms of the partnership, Evotec and UKE will leverage their complementary strengths for the development of a new cell therapy approach using Engineered Heart Tissue for the treatment of heart failure. Heart failure is frequently associated with ischemic heart disease and often comes with a poor prognosis. Mortality is comparable to that of the most common cancers, with <50% 4-year survival. Treatment of patients suffering from heart failure is expected to deliver significant patient benefit through improved heart function, ultimately leading to an improved prognosis.

Evotec leverages its industry-leading human induced pluripotent stem cells ("hiPSCs") platform to establish GMP-compatible process development and upscaling for large-scale generation of clinical-grade heart muscle cells known as cardiomyocytes. Evotec will also contribute genetically modified GMP iPSC lines, which contain alterations preventing rejection of the cardiomyocyte-containing product by patient immune systems ("cloaking"), and include additional safety mechanisms to control unwanted proliferation of graft cells. By using these GMP-grade iPSC lines, the project will deliver off-the-shelf products, which can be implanted in broad patient populations with little to no immunosuppression. UKE applies its proprietary Giga Patch Method for the generation of fully functional heart tissue suitable for cardiac transplantation. Further in vivo validation and development activities will be shared jointly between the partners. Evotec will be responsible for GMP and pre-clinical activities as well as for any subsequent partnering of the programme.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are very excited about this collaboration with the UKE. Both Evotec and UKE have developed and refined their respective technology platforms over a number of years and have now decided to jointly drive this cardiac cell therapy programme towards clinical development. We are confident that this partnership will deliver a new therapeutic option for patients who suffer from heart failure."

Prof. Dr Thomas Eschenhagen, Director of the Institute of Experimental Pharmacology and Toxicology at UKE, added: "We are excited about the new opportunities the partnership with Evotec will create. After having worked on means to repair injured heart by 3-dimensional heart muscle patches for over two decades, joining forces with Evotec and its industrialized hiPSC platform and new cell lines, will bring this development to a new stage. We are aiming at the most efficient and safest therapy in the field."

"We are very happy to see a scientific success story advance to a feat of technology transfer. Translation of scientific insights into therapeutic options is a key mission of our University Medical Center", says Prof. Dr Blanche Schwappach-Pignataro, the Dean of Faculty of Medicine of the UKE.

No financial terms of the agreement were disclosed.

About heart failure Heart failure is a severe global health burden with more than 26 million people suffering with the condition worldwide, disproportionately affecting elderly people. While there are options to treat heart failure both medicinally and with devices, there is currently no treatment that targets the cause of the disease or significantly slows down its progression.

About Evotec and iPSC Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. Pluripotent stem cells hold great promise in the field of regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.

Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry. Evotec's iPSC platform has been developed over the last years with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach the highest industrial standards, and to use iPSC-based cells in cell therapy approaches via the Company's proprietary EVOcells platform.

ABOUT THE MEDICAL CENTER HAMBURG-EPPENDORF (UKE) Since its foundation in 1889, the Medical Center Hamburg-Eppendorf (UKE) has been one of the leading clinics in Europe. With about 13,600 employees, the UKE is one of the largest employers in Hamburg. Each year, the UKE treats around 511,000 patients, 106,000 of whom are inpatients and 405,000 outpatients. The emphasis in UKE's research are the neurosciences, cardiovascular research, care research, oncology, as well as infections and inflammations. Other potential areas of the UKE are molecular imaging and skeletal biology research. The UKE trains about 3,400 medical specialists and dentists. Knowledge, Research, Healing through Shared Competence: The UKE | http://www.uke.de

ABOUT EVOTEC SE Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,500 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to http://www.evotec.com and follow us on Twitter @Evotec.

FORWARD-LOOKING STATEMENTS Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Media Contact Evotec SE: Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

IR Contact Evotec SE: Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com

04.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Continued here:
Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy f - PharmiWeb.com

Breakthrough stem cell therapy may reverse life-threatening conditions in dogs – Study Finds

By adminFebruary 4, 2021Induced Pluripotent Stem Cells

SAKAI, Japan Just like humans, mans best friend deals with all sorts of chronic and degenerative conditions as they age. For dogs however, scientists have fewer ways of reversing life-threatening illnesses compared to human patients. Now, a team in Japan has successfully developed a technique which creates new stem cells from a dogs blood. Their study opens the door for new therapies which can regenerate a dogs body just like stem cells do in people.

In humans, these baby cells have the potential to grow into a variety of specialized cells, an ability called pluripotency. After scientists transplant these stem cells into a patient, they guide their differentiation into the specific kind of cells which completes their task. The new cells can then regenerate damaged tissues, reversing the effect of various diseases. While stem cell research for humans is a widely studied topic, researchers say little work is done with pets.

The new study, led by Associate Professor Shingo Hatoya from Osaka Prefecture University, focuses on induced pluripotent stem cells (iPSCs) in canine blood samples. Study authors say iPSCs are a type of stem cell which can be programmed from a developed cell. Scientists can do this by introducing specific genes into the cell. The genes code for specific proteins (transcription factors) which trigger the change from a developed cell into a pluripotent stem cell.

Another good thing about iPSCs is they multiply rapidly, providing a sustainable supply of usable stem cells for medical treatments.

We successfully established an efficient and easy generation method of canine iPSCs from peripheral blood mononuclear cells Dr. Hatoya in a university release.

The study authors call this a breakthrough in veterinary science. Hatoya hopes in the near future, it may be possible to perform regenerative medicinal treatments in dogs.

This isnt the first time scientists have experimented with iPSCs from canine blood cells. Researchers say these attempts used viral vectors to deliver the stem cell-triggering transcription factors.

In the new study, the Japanese team tested a different combination of factors to create pluripotency. Most importantly, researchers say they had to control how the reprogrammed cells multiplied in the host.

Scientists use viral vectors, which encode these transcription factors, to infect cells and convert them into iPSCs. Unfortunately, since these vectors merge with the hosts genetic material, these pluripotency factors can actually cause tumors if they are transplanted into a dog.

To avoid this, researchers created footprint-free stem cells using a special type of viral vector. This particular vector generates iPSCs without mixing with the hosts genes. It can also be automatically silenced by microRNAs in the cells. The OPU team grew these cells in a special environment which contained a small-molecule cocktail that enhances pluripotency. The results successfully produced cells which developed germ layers the basis of all organs.

Study authors say their findings provide a clear path to easy stem cell treatments for dogs. However, they add that their research may also have a ripple effect in the human medical world as well.

We believe that our method can facilitate the research involving disease modeling and regenerative therapies in the veterinary field, Dr. Hatoya says. Dogs share the same environment as humans and spontaneously develop the same diseases, particularly genetic diseases.

The team believes finding a cure for diseases in mans best friend may also open the door to curing illnesses still plaguing mankind.

The study appears in the journal Stem Cells and Development.

Go here to read the rest:
Breakthrough stem cell therapy may reverse life-threatening conditions in dogs - Study Finds

SLAS Technology Special Collection on Artificial Intelligence in Process Automation Available Now – Newswise

By adminFebruary 4, 2021Induced Pluripotent Stem Cells

Newswise Oak Brook, IL The February edition of SLAS Technology is a special collection of articles focused on Artificial Intelligence in Process Automation by Guest Editor Cenk ndey, Ph.D. (Amgen, Thousand Oaks, CA, USA).

This SLAS Technology special collection targets the use of artificial intelligence (AI) techniques and technologies as applied specifically to drug discovery, automated gene editing and machine learning. As AI becomes increasingly more prevalent in research, medicine and even everyday life, laboratory automation has gone beyond hardware advancements toward new levels of precision and complexity. Beyond research, AI serves as a powerful tool for clinicians diagnosing and treating patients in a medical setting. The AI advancements presented in this issue highlight the wide spectrum of medical AI breakthroughs.

This months issue of SLAS Technology also celebrates the top 10 most-cited articles within the journals history. Over the past decade, the publications priority has been to provide a platform for researchers to share technological advancements as well as a resource to continually share the impact of technology on life sciences and biomedical research.

The February issue of SLAS Discovery includes nine articles of original research in addition to the cover article.

Articles of Original Research include: